No worries Red, I enjoyed your commentary.
Despite the disappointing SP, I am optimistic as ever about our prospects!…WGT!

Thanks for the new info RedSholder!

From BB on Stock twts-discussion with IR.
Everything is Alzheimer's.
They
are hiring and gathering data.
Just a few patients actually left to
finish the trial!! When for
RESULTS!! He said we could try
for 3rd Quarter to early 4th. .so
September October. is in line
with my thoughts. Rett! They
want an ok to file for approval on
that.. May get news by July!
Parkinson's why full genome
scan? He said we don't need 2000
patients if we can prove with
biomarkers we can get approval
on 500 patients! Excellence
results in 2022 still.. I said you are
waiting for alzheimer's results to
soar the stock then start
Parkinson's . He also felt the
alzheimer's trial can make
Blarcamesine the biggest drug in
history! So my sights remain on
the Alzheimers results. I said the
trial should finish near may 17.
He said that is about right.
. And
later 3rd Q early 4th September
October alzheimer's potentially
pivotal results.

If Dr M ,who usually operates on a pretty tight budget, is hiring for multiple new positions, including positions for sales and marketing, he must have a pretty good idea on where this is going.

Perhaps positive feedback from the Feds.

Make that 5! A3-71 complete a successful P1 as well!

Vice President of marketing, Director-sales….. I like to see those two positions available!

Interesting post from Piotr on stock twts-

“so Chief Scientific Officer
Dr Hammond says that some
patients in trial Phase 26/3 are
recovering from AD and there is
no reaction from the market.
Geat hopes of complete cure die
with every trial and when a
company says it reversed for
some the course of disease there
is silence, this is indeed shocking.
But I bet somebody is
accumulating.”

With RETT EXCELLENCE likely being delayed until NEXT YEAR, it seems that many of us multi year longs are getting frustrated by these never ending delays!
Now we set our sights on AD this fall, not knowing if it will even be accepted as a PH3.

I been here from before the R/S and have amassed a pretty large position and have not sold a single share. I have always been very supportive of Dr Missling but I have to admit, I have become increasingly frustrated with his handling of things lately.

After fumbling the AVATAR situation, there is no excuse not to do a better job with the trial updates!
I understand the Covid/vaccination delays, after a two year delay, recruiting 15 girls can’t possibly take this long.
His misleading timelines are borderline lying to share holders.

Sitting on PD/PDD for two years without any updates or action.
I understand the whole Germain get it right the first time thing, but there seems to be no sense of urgency at all. Any new trials will take YEARS to recruit and conduct.

The latest option grant on “ easy “ conditions has me a little annoyed as well.
I not selling out after this long, and I’m sure all will be forgiven if we ever get an approval or even an NDA.
Come on Dr. Missling! Step it up!

I seem to remember that it was the third week of May but I can’t find it either.

“ The report accompanying the legislation listed Rett syndrome as a topic eligible for research funding through the U.S. Department of Defense (DoD) Peer-Reviewed Medical Research Program (PRMRP), “

Remember a few months ago when Dr. Randy Hagerman mentioned something about a DoD funded Fragile X trial for A2-73.

Did anyone listen to the Cantor Virtual Rare Disease Summit today?

Someone on stock twts said TGD said Anavex will be starting 10 new trials.

Since last July trial update, they went from 69 to 84 participants, changed the age from 5-18 yrs to 5-17 yrs, and added Melboure, Aus, Alberta, Can and BC, Can.
It never listed the UK sites. Perhaps they gave up on them.

I would personally rather them file the NDA now than wait another year, waiting for the excellence data. An approval gets their foot in the door and the revenue flowing, might be worth more than the voucher.

WHAT?..we have to wait another year and a half to be rich??….sigh

That chart is way to conservative IMO. Assuming 5% market shares ?

I believe a prevention trial would require a very large n and very lengthy not to mention very expensive.
A large, deep pocket BP partner would probably be needed.

The question is WILL countries like Australia grant approval first? I read somewhere that they usually follow the FDA’s lead on drug approval.

Dr. M said that they are planning a 3-71 trial for AD.
Interesting that AD would be right on the heels of A2-73.
Looks like he is going for the big $$$ indications.

Now that A2-73 was completed several trials, will the data crunching become more streamlined and possibly faster TLD readout’s with each new trial?

The Biotech Laymen like myself, have a hard time understanding why , with advanced computer technology, it takes months to report the data. I understand the whole get it right the first time. Dot every i and cross every t thing, but there just doesn’t seem to be much urgency.

Approvals and Revenue are what will finally light a fire to the share price. It’s apparent that great trial results for AVXL are largely ignored unlike other biotechs

It’s Putin’s fault!

Is it November yet? Looks like a long few months ahead.

https://www.newsmax.com/us/alzheimers-biogen-urge-us/2022/03/13/id/1060932/

Wow! Someone really likes the news about the dog and pony show virtual forum!

PDD/PD, Fragile x, A3-71and undisclosed rare disease trial news is still not being mentioned. Seems strange to me. Maybe because of partnership talks? RETT approval discussion talk with the FDA?

“The Phase 2/3 EXCELLENCE trial includes a 12-week period with either Anavex 2-73 or placebo, after which children may enroll in an extension study of 48 weeks “

EXCELLENCE is 12 weeks not 7

Going to need one of the largest accounting firms to count all that money coming in over the next few years!!

https://www.gurufocus.com/news/1657835/anavex-life-sciences-announces-change-of-auditor-to-grant-thornton-llp

How about using one of the less restrictive countries for the final 15 trial participants?

DRUG APPROVAL, REVENUE or A deep pocket BP partnership are the only way Wall Street will value Anavex at its proper valuation !…Imo

Awesome..from Twitter-

TheAnavexDr.
@TheAnavexDr
Replying to
@adamfeuerstein
I’ll ask again since you didn’t answer last week: I will donate $10,000 to the charity of your choice if you are willing to have a discussion in regards to the $AVXL science. You can choose the format and topics. What do you say?
5:06 PM · Feb 9, 2022·Twitter for iPhone

“Planned initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical study.”

Gloom and despair right Investor?

https://ih.advfn.com/p.php?pid=nmona&article=87229998

https://www.tipranks.com/news/blurbs/anavex-life-sciences-avxl-receives-a-buy-from-dawson-james?mod=mw_quote_news

Didn’t I read somewhere that Rett seizures are more frequent in younger girls? If so , the EXCELLENCE trial hopefully will reduce seizures more than 50 percent.

I hope adam f is on the list!
https://news.bloomberglaw.com/securities-law/vast-doj-probe-looks-at-almost-30-short-selling-firms-and-allies

Question for the data savy MB posters- how would you rate the AVATAR trial data,from what has been released so far, how would you rate the data 1-10.
1=poor
10=extremely positive
From reading the responses, I’m guessing an 8?